GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » 3-Year EBITDA Growth Rate

Eupraxia Pharmaceuticals (TSX:EPRX) 3-Year EBITDA Growth Rate : -94.20% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals 3-Year EBITDA Growth Rate?

Eupraxia Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was C$-0.20.

During the past 3 years, the average EBITDA Per Share Growth Rate was -94.20% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -14.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Eupraxia Pharmaceuticals was 25.50% per year. The lowest was -94.20% per year. And the median was -22.45% per year.

Competitive Comparison of Eupraxia Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Eupraxia Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eupraxia Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eupraxia Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Eupraxia Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.


Eupraxia Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Eupraxia Pharmaceuticals  (TSX:EPRX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Eupraxia Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals (TSX:EPRX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (TSX:EPRX) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
NEOE:MMED XCNQ:DTC TSXV:NGEN TSX:ONC TSX:BCT XCNQ:MSET TSXV:ARCH TSXV:MIR TSXV:DMT TSX:HBP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
EPRXF:USA
Address
201-2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Website
https://www.eupraxiapharma.com
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.